Neurotrophic factors in women with crack cocaine dependence during early abstinence: The role of early life stress

Journal of Psychiatry and Neuroscience

Volumn 39, Issue 3, 2014, Pages 206-214

  Viola, Thiago Wendt ^a   Tractenberg, Saulo Gantes ^a   Levandowski, Mateus Luz ^a   Pezzi, Júlio Carlos ^b   Bauer, Moisés Evandro ^a   Teixeira, Antonio Lúcio ^c   Grassi Oliveira, Rodrigo ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIS; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; COCAINE;

ABSTINENCE; ADDICTION SEVERITY INDEX; ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BECK DEPRESSION INVENTORY; BODY MASS; CHILD SEXUAL ABUSE; CHILDHOOD TRAUMA QUESTIONNAIRE; CLINICAL ASSESSMENT; COCAINE DEPENDENCE; CONTROLLED STUDY; DETOXIFICATION; EARLY LIFE STRESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MENSTRUAL CYCLE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; BLOOD; CHILD; MENTAL STRESS; STATISTICAL MODEL; TIME; WITHDRAWAL SYNDROME;

ADULT; CHILD; CHILD ABUSE, SEXUAL; COCAINE-RELATED DISORDERS; CRACK COCAINE; FEMALE; FOLLOW-UP STUDIES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; LINEAR MODELS; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; NEUROTROPHIN 3; STRESS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 84900835247     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.130027     Document Type: Article

References (74)

1. Heberlein A, Muschler M, Wilhelm J, et al. BDNF and GDNF serum levels in alcohol-dependent patients during withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1060-1064.
2. Corominas M, Roncero C, Ribases M, et al. Brain-derived neuro -trophic factor and its intracellular signaling pathways in cocaine addiction. Neuropsychobiology 2007;55:2-13.
3. Angelucci F, Ricci V, Pomponi M, et al. Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J Psychopharmacol 2007;21:820-825.
4. D'Sa C, Fox HC, Hong AK, et al. Increased serum brain-derived neurotrophic factor is predictive of cocaine relapse outcomes: a prospective study. Biol Psychiatry 2011;70:706-711.
5. Pierce RC, Pierce-Bancroft AF, Prasad BM. Neurotrophin-3 contributes to the initiation of behavioral sensitization to cocaine by activating the Ras/Mitogen-activated protein kinase signal trans-duction cascade. J Neurosci 1999;19:8685-8695.
6. Grimm JW, Lu L, Hayashi T, et al. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 2003;23:742-747.
7. Covington HE 3rd, Maze I, Sun H, et al. A role for repressive his-tone methylation in cocaine-induced vulnerability to stress. Neuron 2011;71:656-670.
8. Corominas-Roso M, Roncero C, Eiroa-Orosa FJ, et al. Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence. Eur Neuropsychopharmacol 2012 Oct. 2 [Epub ahead of print].
9. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 2007;41:979-990.
10. Heymach JV, Jr., Barres BA. Neurotrophins moving forward. Nature 1997;389:789-791.
11. Nockher WA, Renz H. Neurotrophins in clinical diagnostics: pathophysiology and laboratory investigation. Clin Chim Acta 2005;352:49-74.
12. Jansson LC, Louhivuori L, Wigren HK, et al. Brain-derived neu-rotrophic factor increases the motility of a particular N-methyl-D-aspartate /GABA-responsive subset of neural progenitor cells. Neuroscience 2012;224:223-234.
13. Lesemann A, Reinel C, Huhnchen P, et al. MPTP-induced hip-pocampal effects on serotonin, dopamine, neurotrophins, adult neurogenesis and depression-like behavior are partially influenced by fluoxetine in adult mice. Brain Res 2012;1457:51-69.
14. Perreault ML, Jones-Tabah J, O'Dowd BF, et al. A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex. Int J Neuropsychopharmacol 2013;16:477-483.
15. Miczek KA, Nikulina EM, Shimamoto A, et al. Escalated or suppressed cocaine reward, tegmental BDNF, and accumbal dopamine caused by episodic versus continuous social stress in rats. J Neurosci 2011;31:9848-9857.
16. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-1413.
17. Schmidt HD, Sangrey GR, Darnell SB, et al. Increased brain-derived neurotrophic factor (BDNF) expression in the ventral tegmental area during cocaine abstinence is associated with increased histone acetylation at BDNF exon I-containing promoters. J Neurochem 2012;120:202-209.
18. Graham DL, Edwards S, Bachtell RK, et al. Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 2007;10:1029-1037.
19. Sadri-Vakili G, Kumaresan V, Schmidt HD, et al. Cocaine-induced chromatin remodeling increases brain-derived neurotrophic factor transcription in the rat medial prefrontal cortex, which alters the reinforcing efficacy of cocaine. J Neurosci 2010;30:11735-11744.
20. Grassi-Oliveira R, Ashy M, Stein LM. Psychobiology of childhood maltreatment: effects of allostatic load? Rev Bras Psiquiatr 2008;30:60-68.
21. Dannlowski U, Stuhrmann A, Beutelmann V, et al. Limbic scars: long-term consequences of childhood maltreatment revealed by functional and structural magnetic resonance imaging. Biol Psychiatry 2012;71:286-293.
22. McEwen BS. Brain on stress: how the social environment gets under the skin. Proc Natl Acad Sci U S A 2012;109(Suppl 2):17180-17185.
23. Cirulli F, Francia N, Berry A, et al. Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates. Neurosci Biobehav Rev 2009;33:573-585.
24. Rakofsky JJ, Ressler KJ, Dunlop BW. BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder co-morbidity. Mol Psychiatry 2012;17:22-35.
25. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci 2008;1141:105-130.
26. Del-Ben CM, Vilela JA, Crippa JA, et al. Reliability of the Structured Clinical Interview for DSM-IV - Clinical Version translated into Portuguese. Br J Psychiatry 2001;23:156-159.
27. Grassi-Oliveira R, Stein LM, Pezzi JC. [Translation and content validation of the Childhood Trauma Questionnaire into Portuguese language]. Rev Saude Publica 2006;40:249-255.
28. Bernstein DP, Stein JA, Newcomb MD, et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl 2003;27:169-190.
29. Gorenstein C, Andrade L. Validation of a Portuguese version of the Beck Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. Braz J Med Biol Res 1996;29:453-457.
30. Kampman KM, Volpicelli JR, McGinnis DE, et al. Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav 1998;23:449-461.
31. Kessler F, Cacciola J, Alterman A, et al. Psychometric properties of the sixth version of the Addiction Severity Index (ASI-6) in Brazil. Rev Bras Psiquiatr 2012;34:24-33.
32. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980;168:26-33.
33. Lommatzsch M, Zingler D, Schuhbaeck K, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005;26:115-123.
34. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11:1169-1180.
35. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380:252-255.
36. Little KY, Ramssen E, Welchko R, et al. Decreased brain dopamine cell numbers in human cocaine users. Psychiatry Res 2009;168:173-180.
37. Garcia RC, Dati LM, Fukuda S, et al. Neurotoxicity of anhydroec-gonine methyl ester, a crack cocaine pyrolysis product. Toxicol Sci 2012;128:223-234.
38. Meaney MJ, Brake W, Gratton A. Environmental regulation of the development of mesolimbic dopamine systems: a neurobiological mechanism for vulnerability to drug abuse? Psychoneuroendocrinology 2002;27:127-138.
39. Hendricks S, Ojuka E, Kellaway LA, et al. Effect of maternal separation on mitochondrial function and role of exercise in a rat model of Parkinson's disease. Metab Brain Dis 2012;27:387-392.
40. Ognibene E, Adriani W, Caprioli A, et al. The effect of early maternal separation on brain derived neurotrophic factor and mono -amine levels in adult heterozygous reeler mice. Prog Neuropsycho -pharmacol Biol Psychiatry 2008;32:1269-1276.
41. Womersley JS, Hsieh JH, Kellaway LA, et al. Maternal separation affects dopamine transporter function in the spontaneously hypertensive rat: an in vivo electrochemical study. Behav Brain Funct 2011;7:49.
42. Gerra G, Leonardi C, Cortese E, et al. Childhood neglect and parental care perception in cocaine addicts: relation with psychiatric symptoms and biological correlates. Neurosci Biobehav Rev 2009;33:601-610.
43. Gerra G, Leonardi C, Cortese E, et al. Homovanillic acid (HVA) plasma levels inversely correlate with attention deficit-hyperactiv-ity and childhood neglect measures in addicted patients. J Neural Transm 2007;114:1637-1647.
44. Morrow BA, Roth RH, Redmond DE, et al. Impact of methamphet-amine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease. Neuroscience 2011;189:277-285.
45. Uchida S, Hara K, Kobayashi A, et al. Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 2011;69:359-372.
46. Carnicella S, Ron D. GDNF-a potential target to treat addiction. Pharmacol Ther 2009;122:9-18.
47. McGinty JF, Whitfield TW, Jr., Berglind WJ. Brain-derived neurotrophic factor and cocaine addiction. Brain Res 2010;1314: 183-193.
48. Kumar A, Choi KH, Renthal W, et al. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 2005;48:303-314.
49. Schroeder FA, Penta KL, Matevossian A, et al. Drug-induced activation of dopamine D(1) receptor signaling and inhibition of class I/II histone deacetylase induce chromatin remodeling in reward circuitry and modulate cocaine-related behaviors. Neuropsycho -pharmacology 2008;33:2981-2992.
50. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-1080.
51. Shirayama Y, Chen AC, Nakagawa S, et al. Brain-derived neuro -trophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002;22:3251-3261.
52. Gabriele A, See RE. Lesions and reversible inactivation of the dor-solateral caudate-putamen impair cocaine-primed reinstatement to cocaine-seeking in rats. Brain Res 2011;1417:27-35.
53. Dobi A, Seabold GK, Christensen CH, et al. Cocaine-induced plasticity in the nucleus accumbens is cell specific and develops without prolonged withdrawal. J Neurosci 2011;31:1895-1904.
54. Berhow MT, Russell DS, Terwilliger RZ, et al. Influence of neuro -trophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neuroscience 1995; 68:969-979.
55. Sauer H, Wong V, Bjorklund A. Brain-derived neurotrophic factor and neurotrophin-4/5 modify neurotransmitter-related gene expression in the 6-hydroxydopamine-lesioned rat striatum. Neuroscience 1995;65:927-933.
56. Skaper SD. The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol 2012;846:1-12.
57. Hefti F. Pharmacology of neurotrophic factors. Annu Rev Pharmacol Toxicol 1997;37:239-267.
58. Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 2000;14:2919-2937.
59. Cabelli RJ, Hohn A, Shatz CJ. Inhibition of ocular dominance column formation by infusion of NT-4/5 or BDNF. Science 1995;267: 1662-1666.
60. Hadjiconstantinou M, McGuire L, Duchemin AM, et al. Changes in plasma nerve growth factor levels in older adults associated with chronic stress. J Neuroimmunol 2001;116:102-106.
61. Xiong P, Zeng Y, Wan J, et al. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res 2011;189:72-76.
62. Martino M, Rocchi G, Escelsior A, et al. NGF serum levels variations in major depressed patients receiving duloxetine. Psycho -neuro endocrinology 2013;38:1824-1828.
63. Diniz BS, Teixeira AL, Machado-Vieira R, et al. Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry 2013;21:493-496.
64. Wang X, Hou Z, Yuan Y, et al. Association study between plasma GDNF and cognitive function in late-onset depression. J Affect Disord 2011;132:418-421.
65. Tseng PT, Lee Y, Lin PY. Age-associated decrease in serum glial cell line-derived neurotrophic factor levels in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2013;40:334-339.
66. Otsuki K, Uchida S, Watanuki T, et al. Altered expression of neuro trophic factors in patients with major depression. J Psychiatr Res 2008;42:1145-1153.
67. Hock C, Heese K, Muller-Spahn F, et al. Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Mol Psychiatry 2000;5:510-513.
68. Alleva E, Petruzzi S, Cirulli F, et al. NGF regulatory role in stress and coping of rodents and humans. Pharmacol Biochem Behav 1996;54:65-72.
69. Smith MA, Makino S, Kvetnansky R, et al. Stress and glucocorti-coids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995;15:1768-1777.
70. Sartorius A, Hellweg R, Litzke J, et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009;42: 270-276.
71. Pan W, Banks WA, Kastin AJ. Permeability of the blood-brain barrier to neurotrophins. Brain Res 1998;788:87-94.
72. Piccinni A, Marazziti D, Catena M, et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 2008;105:279-283.
73. Yasui-Furukori N, Tsuchimine S, Nakagami T, et al. Association between plasma paroxetine concentration and changes in plasma brain-derived neurotrophic factor levels in patients with major depressive disorder. Hum Psychopharmacol 2011;26:194-200.
74. Lu L, Wang X, Wu P, et al. Role of ventral tegmental area glial cell line-derived neurotrophic factor in incubation of cocaine craving. Biol Psychiatry 2009;66:137-145.